How To Improve Patient Recruitment in Clinical Trials

Roughly 80% of clinical trials miss their enrolment timelines, and around 30% of sites never enrol a single participant. The cost of those delays runs into millions per day for late stage trials, and the cost to patients waiting for new treatments is harder to quantify but easily larger.

Recruitment is often treated as a marketing problem. It’s actually a study design problem. The teams who consistently meet enrolment targets aren’t running better ad campaigns. They’re running trials that are easier to join, easier to stay in, and easier to understand.

This guide covers 9 evidence based ways to improve patient recruitment in clinical trials, drawn from the studies our team has supported across Australia and globally.

We’ll look at why traditional recruitment is breaking. We’ll cover what to change in protocol design and digital workflow. We’ll show how to recruit fairly across diverse communities, and how to measure whether your changes are actually working.

The BRACE Trial reached 6,000 participants in five countries and held adherence above 90%. We’ll show you how, and what you can borrow.

Why patient recruitment fails in most clinical trials

The standard recruitment story goes like this. A protocol is designed by a clinical team, eligibility criteria are written conservatively, sites are activated, paper consent forms are printed, and recruitment begins.

Within a few months, sponsors notice the numbers are behind. Budgets are spent on more advertising. Timelines slip. Some sites are dropped for poor performance.

The Tufts Center for the Study of Drug Development has reported for years that the majority of trials don’t hit enrolment goals on time. The US Food and Drug Administration has flagged that participation across many therapy areas remains low and unrepresentative of the populations who actually use the eventual treatments.

These aren’t isolated problems. They’re systemic.

There are three patterns we see most often. Eligibility criteria are written for a perfect protocol participant, not a real one. Pre-screening is paper based and slow, so screen failure rates climb. And the participant experience itself feels like extra work, so people drop out before they ever produce useful data.

Each problem on its own is solvable. Together they explain most missed timelines.

A useful way to think about it is the screen failure tax. Every patient who completes screening but doesn’t enrol still costs you site time, staff time, and recruitment spend. Cutting that tax is often a faster path to your target than buying more reach.

9 strategies to improve patient recruitment in clinical trials

The strategies below work together. Pick one, see it through, then layer the next. Each one includes why it works, how to apply it, and what to watch for.

1. Design eligibility criteria for the real world, not the protocol committee

Why it works: Overly narrow criteria are the single biggest driver of high screen failure rates. Each extra criterion reduces the available pool, often without adding scientific value.

How to apply: Walk every inclusion and exclusion criterion through a simple test. What population question does this criterion answer? Would removing it change the validity of the primary endpoint? If not, broaden it or remove it. Run the protocol past three clinicians who treat the target condition daily, not just methodologists.

What to watch for: Don’t loosen criteria that protect participant safety. Broadening should be deliberate, documented, and reviewed by your ethics committee.

2. Pre-screen digitally to cut screen failures

Why it works: A two minute mobile pre-screen replaces a thirty minute paper visit. Patients self select out before they take a site appointment, and your team focuses attention on people who are likely to qualify.

How to apply: Build a short digital screener with the criteria most likely to disqualify someone. Run it before any phone call or site visit. Many programs cut their screen failure rate by half once they move pre-screening online.

Most teams build their screener with WeGuide’s Form Builder and route eligible participants into our digital screening module.

What to watch for: Privacy. A pre-screen captures health information. Use a platform with proper consent flows, encrypted storage, and audit trails.

3. Make participation easier with decentralised and hybrid trial design

Why it works: When participants can complete most of a trial from home, geography stops being a barrier. The recruitment pool expands, and dropouts driven by travel and time off work fall.

How to apply: Look at every visit on your schedule of assessments. Mark which visits genuinely need a site, which can move to telehealth, and which can be replaced with at home data capture. A decentralised clinical trial platform lets you mix on site and remote visits inside one protocol.

What to watch for: Some assessments still need a site, and some populations have lower digital access. Build a hybrid design that respects both.

4. Recruit in the languages your participants actually speak

Why it works: A study only available in English will systematically miss culturally and linguistically diverse communities, who are often the populations you most need to include for generalisable results.

How to apply: Translate consent, screening, education, and data capture into the languages spoken in your catchment area. Use professional clinical translators, not machine translation. Australia’s INHERIT study used a multi-language clinical trial platform to engage CALD families during the pandemic, in their own language, on their own phone.

What to watch for: Translation isn’t enough on its own. Cultural review of imagery, examples, and tone is what turns a translated form into one that actually gets completed.

5. Use multichannel digital outreach and referral pathways

Why it works: Different populations live on different channels. A search ad reaches one segment, a community Facebook group reaches another, a GP referral letter reaches a third. The teams who hit timelines run all of them at once.

How to apply: Plan your outreach mix the same way you plan your protocol. Search ads for high intent searches like “clinical trial for X”. Social ads for awareness. Patient advocacy partnerships for rare conditions. Trusted GP referral pathways for sensitive conditions. Track each channel separately and shift budget toward the ones that produce enrolled participants, not just clicks.

What to watch for: Cost per click is not a useful metric for trials. Cost per consented and enrolled participant is the only number that matters.

6. Replace paper consent with eConsent built for comprehension

Why it works: Paper consent is long, intimidating, and produces low real comprehension. Many participants sign without fully understanding the trial, which raises ethical risk and increases later dropout. Electronic informed consent uses video, plain language, and short comprehension checks to support genuine understanding.

How to apply: Move to a proper electronic informed consent workflow with version control and audit trails, not just a PDF on a tablet. See our eConsent best practices guide for design patterns that work.

What to watch for: Regulatory requirements vary by jurisdiction. Confirm your eConsent design with your IRB or HREC before you launch.

7. Build trust through clear patient education

Why it works: People say yes to trials they understand. They say no, or they drop out, when the experience feels opaque. Short, well timed educational content during onboarding and at key milestones answers the questions participants are too polite to ask.

How to apply: Map the moments where participants typically have questions. After consent. Before the first study drug dose. Before the first follow up. Send a short video, a one page summary, or a chat option at each point. Treat education as part of the protocol, not a marketing afterthought.

What to watch for: Don’t overload. Two minutes of clear content beats a ten minute information dump every time.

8. Treat retention as part of recruitment, not the next phase

Why it works: A trial that loses 25% of participants in the first three months has to recruit 25% more people to hit the same data target. Retention is the cheapest form of recruitment you can run.

How to apply: From day one, design for the moments that drive dropout. Confusing instructions, surprise visit lengths, slow reimbursement, no human contact between visits. Use automated reminders, predictable schedules, and a real person participants can message. Studies that pair good design with patient engagement software often see adherence above 85%, sometimes above 90%.

What to watch for: Reminders alone don’t keep people engaged. Reminders that respect time of day, language, and preferred channel do.

9. Measure, learn, and iterate weekly, not monthly

Why it works: Most trial teams review recruitment monthly. By then, four weeks of an underperforming channel has already been spent. Weekly review catches problems while there’s still time to act.

How to apply: Build a simple weekly dashboard. Reach by channel, screen rate, eligibility rate, consent rate, enrolment rate, and dropout rate. Hold a 30 minute meeting each week, look at the numbers, and decide one thing to change.

What to watch for: Don’t change five things at once. You won’t know which one worked.

How decentralised trials change the recruitment maths

A decentralised clinical trial isn’t just a remote version of a traditional trial. It’s a different recruitment model. When site visits are no longer the bottleneck, the recruitment funnel widens dramatically.

Take the BRACE Trial, run by the Murdoch Children’s Research Institute. Its goal was to test whether the BCG vaccine could reduce the severity of COVID-19 symptoms in healthcare workers. It needed to launch fast, run across five countries, and keep participants engaged for months without traditional site visits.

The trial deployed in 6 weeks. It enrolled more than 6,000 participants. Adherence sat above 90%.

None of that happens with paper protocols and clinic only visits. It happens because participants could screen, consent, complete daily symptom diaries, and report adverse events from their own phone.

You can read the full BRACE trial case study for the operational detail.

A simple way to see the difference is side by side.

The lesson for any team trying to improve patient recruitment in clinical trials is straightforward. If your protocol design assumes site visits, your recruitment ceiling is set by site capacity. Move what can move to remote, and the ceiling lifts.

Recruiting underrepresented populations in clinical trials

Diversity in trials matters scientifically and ethically. Treatments tested only on narrow populations don’t always work the same way in the patients who eventually use them.

The US FDA has been clear about this in its guidance on enhancing participation in clinical trials, and similar guidance exists from the NIH and EMA.

The WeGuide team supported the INHERIT multilingual COVID-19 study, an Australian research project that needed to recruit families from culturally and linguistically diverse backgrounds. The platform delivered consent, surveys, and education in multiple languages, on participants’ own devices.

The result was a study that reflected the actual community it was trying to serve, not just the English speaking subset.

A few practical patterns help most teams.

• Translate every participant facing artefact, not just consent.
• Recruit through community organisations and trusted local clinicians, not only through national channels.
• Match interviewer or coordinator background to the community where appropriate.
• Use mobile first design, because many CALD communities access health information primarily through phones.

Inclusive recruitment isn’t a separate workstream. It’s a quality bar applied to all of the strategies above.

How to measure patient recruitment performance

If you want to improve patient recruitment in clinical trials, you have to measure it consistently. Most teams measure too late and too narrowly.

A useful funnel has six stages.

1. Reach: how many people saw or were referred to the trial
2. Pre-screen complete: how many started a screener
3. Eligible: how many passed pre-screening
4. Consented: how many completed eConsent
5. Enrolled: how many were randomised or began the protocol
6. Retained at week 12 (or your relevant milestone): how many were still active

Watch the conversion rates between every stage. A drop from reach to pre-screen suggests messaging is off. A drop from eligible to consented suggests the consent process is too heavy. A drop from consented to retained suggests the early protocol experience is harder than people expected.

Add two cost metrics: cost per consented participant and cost per retained participant. The second matters far more than the first. A channel that produces cheap consents but no retained participants is more expensive than it looks.

Tools like our analytics dashboard can roll these metrics up in real time, but you don’t need a particular platform to start. A weekly spreadsheet review will catch most problems early enough to act.

How WeGuide supports patient recruitment and retention

We’re a patient engagement platform built for clinical research, not a recruitment agency. What we provide is the operational layer that turns the strategies above into a working trial.

That includes digital pre-screening, eConsent with version control and audit trails, and multilingual onboarding. It also covers ePRO and symptom diaries on participant phones, telehealth visits, automated reminders, and analytics on the recruitment funnel.

We’re TGA Class I certified medical device software. We’re ISO 27001:2022 compliant, and we support FDA 21 CFR Part 11 requirements.

The teams we partner with come to us because they need to launch in weeks, not months, and they need adherence high enough to make the data useful. The BRACE Trial deployed in 6 weeks. GenV, Australia’s largest population health study, has more than 100,000 families actively engaged. INHERIT recruited across multiple languages during a pandemic.

We aren’t the reason those studies succeeded. We’re the platform that helped the research teams do their best work.

If you’d like to see how this might apply to your trial, book a short demo with our team.

Bring your protocol. We’ll walk you through the recruitment funnel using your study, not a generic mock up.

Frequently asked questions

What is the biggest challenge in patient recruitment?

The biggest single challenge is misalignment between protocol design and the real world. Eligibility criteria written for a perfect participant, schedules that demand frequent site visits, and consent processes that are hard to understand all push people out of the funnel. Fixing protocol design typically improves recruitment more than fixing advertising.

How long does patient recruitment take in a clinical trial?

It varies widely by therapy area and design, but most sponsors plan for 12 to 24 months for moderate Phase II and Phase III trials. About 80% of trials miss this plan. Decentralised and hybrid designs can compress the timeline meaningfully, especially for studies that don’t require frequent in person assessments.

What percentage of clinical trials fail because of recruitment?

Recruitment is the most common reason trials are delayed, redesigned, or terminated. Industry analyses from Tufts CSDD and others have shown that around 80% of trials miss enrolment timelines, and roughly 1 in 5 trials are terminated early in part because of recruitment shortfalls.

How do you improve diversity in clinical trial recruitment?

Translate the trial, partner with trusted community organisations, recruit through GPs and clinicians who serve the target population, and design participation to fit real lives. Mobile first eConsent, flexible visit schedules, and remote data collection make trials reachable for people who can’t take time off work or travel to academic centres.

Conclusion

Improving patient recruitment in clinical trials isn’t about finding a clever new ad channel. It’s about removing friction, top to bottom. Design eligibility criteria for real participants, pre-screen digitally, move what can move to remote, recruit in the languages your community speaks, replace paper consent with eConsent built for comprehension, treat education and retention as part of the protocol, and measure weekly so you can act in time.

The studies that consistently hit enrolment targets share a pattern. Their protocols are designed for participants, not just for the methods section. Their digital workflows respect participant time. Their teams iterate fast on what the data tells them.

The BRACE Trial, GenV, and INHERIT all show what’s possible when those pieces line up.

If you’re planning a trial and want help applying these strategies to your protocol, our clinical trial solutions team would be glad to talk it through.

The right platform doesn’t replace good study design. It makes good study design easier to deliver.

‍